Canada - English - Health Canada

sandoz canada incorporated - neostigmine methylsulfate - solution - 0.5mg - neostigmine methylsulfate 0.5mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

sandoz canada incorporated - neostigmine methylsulfate - liquid - 1mg - neostigmine methylsulfate 1mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

sandoz canada incorporated - neostigmine methylsulfate - solution - 2.5mg - neostigmine methylsulfate 2.5mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

david bull laboratories (pty) ltd. - neostigmine methylsulfate - liquid - 1mg - neostigmine methylsulfate 1mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

david bull laboratories (pty) ltd. - neostigmine methylsulfate - liquid - .5mg - neostigmine methylsulfate .5mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

fresenius kabi canada ltd - neostigmine methylsulfate - liquid - 1mg - neostigmine methylsulfate 1mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

fresenius kabi canada ltd - neostigmine methylsulfate - liquid - 0.5mg - neostigmine methylsulfate 0.5mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

sandoz canada incorporated - neostigmine methylsulfate - solution - 0.5mg - neostigmine methylsulfate 0.5mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

sandoz canada incorporated - neostigmine methylsulfate - solution - 2.5mg - neostigmine methylsulfate 2.5mg - parasympathomemetic (cholinergic) agents

United States - English - NLM (National Library of Medicine)

a-s medication solutions - neostigmine methylsulfate (unii: 98imh7m386) (neostigmine - unii:3982twq96g) - neostigmine methylsulfate injection, usp, is a cholinesterase inhibitor indicated for the reversal of the effects of nondepolarizing neuromuscular blocking agents after surgery. neostigmine methylsulfate injection, usp, is contraindicated in patients with: - known hypersensitivity to neostigmine methylsulfate (known hypersensitivity reactions have included urticaria, angioedema, erythema multiforme, generalized rash, facial swelling, peripheral edema, pyrexia, flushing, hypotension, bronchospasm, bradycardia and anaphylaxis). - with peritonitis or mechanical obstruction of the intestinal or urinary tract. risk summary there are no adequate or well-controlled studies of neostigmine methylsulfate injection, usp, in pregnant women. it is not known whether neostigmine methylsulfate injection, usp, can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. the incidence of malformations in human pregnancies has not been established for neostigmine as the data are limited. all p